We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -7.02 | -0.94% | 743.75 | 752.1988 | 743.77 | 749.59 | 1,717,211 | 00:54:53 |
From Apr 2019 to Apr 2024
By Josh Beckerman
Eli Lilly & Co. (LLY) reported favorable results for its Cyramza cancer drug in the Phase 3 Reach-2 trial with liver cancer patients.
The company said Reach-2 showed a statistically significant improvement in the primary endpoint of overall survival and in the secondary endpoint of progression-free survival.
The trial evaluated the drug with a biomarker-selected patient population.
Cyramza, currently approved for some patients with conditions including gastric cancer, is being investigated in a development program that has enrolled more than 14,000 patients in over 100 trials.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 18, 2019 20:08 ET (01:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
